suMMARY In eight patients with cirrhosis of the liver and portal hypertension an intravenous infusion of lysine vasopressin induced a rapid increase in the plasma level of the fibrinolytic proenzyme plasminogen activator. In contrast, triglycyl lysine vasopressin (glypressin; GVP), in a dose known to lower portal venous pressure, produced no fibrinolytic response. This lack of fibrinolytic response represents an advantage of GVP over lysine vasopressin in addition to its longer in vivo halflife and lower cardiotoxicity. Clinical trials of GVP in the treatment of bleeding oesophageal varices are needed.
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Lysine vasopressin is the standard drug used to treat bleeding oesophageal varices. Its disadvantages include a short half-life, tachyphylaxis, cardiotoxicity and, in normal subjects, it stimulates the systemic release of the fibrinolytic proenzyme plasminogen activator (Gader et al., 1973b) . Although the recently developed triglycyl form of lysine vasopressin (glypressin; GVP) does not increase the systemic release of plasminogen activator in normal subjects (Cash et al., 1978) , there is no information of its effect in cirrhosis, in which there may be raised levels of this substance and where excessive responses to physiological and pharmacological stimuli may occur (Das and Cash, 1969; Gader et al., 1973a; Robertson, 1971) .
We describe the fibrinolytic response to intravenous lysine vasopressin and GVP in cirrhotic patients with portal hypertension. GVP has a lower cardiotoxicity and a long in vivo half-life (Aronsen et al., 1975; Vosmik et al., 1977) than lysine vasopressin and, if it produced no rise in plasminogen activator in cirrhosis, it would have potential advantages in the control of bleeding oesophageal varices.
Methods

PATIENTS
The clinical and laboratory details of the patients 'Address for correspondence: J. G. Douglas, Gastrointestinal and Liver Service, Royal Infirmary, Edinburgh.
Received for publication 13 February 1979 studied are shown in Table 1 . Patients 1-3 were deemed to have mild liver disease (albumin and vitamin K corrected prothrombin time ratio normal) and patients 4-8 severe liver disease (albumin and prothrombin time ratio abnormal). All but patient 2 had had ascites, and patient 5 had also had encephalopathy. In six patients the diagnosis was confirmed by liver biopsy. Two patients did not undergo liver biopsy; one because of severe lung disease and the other because of the abnormal PTR and thrombocytopenia. Both these patients had clinical and biochemical evidence of chronic liver disease and liver scans compatible with cirrhosis. All eight patients had portal hypertension, as evidenced by oesophageal varices on barium swallow. None was bleeding at the time of the studies.
Eight patients were infused with 10 ,ug lysine vasopressin, five with 750 ,ug GVP (a dose used previously in normal subjects (Cash etal., 1978) ), and eight with 2000 ,ug GVP. All patients gave their informed consent. The infusions were carried out between 9 a.m. and 11 a.m. at intervals of at least a week. All studies were performed in a similar manner. After a 15 minute rest period 50 ml saline were infused into a cubital fossa vein over 15 minutes via a 19 gauge butterfly needle with a Harvard constant infusion pump. The vasopressin, dissolved in 50 ml saline, was then infused over a 15 minute period. Pulse rate and blood pressure were measured at 15 minute intervals before and for 75 minutes after the vasopressin infusion. An electrocardiogram was taken before, every two minutes during each infusion, Range for normal subjects (n = 5) 4-4-13-8 5-5-12-6 20-0-34-9 10-0-24-5 8-0-18-7 -The drug was infused from the fifteenth to the thirtieth minute.
GVP infusions induced no change in euglobulin lysis time, though similar pre-infusion values were seen.
the pulse rate and rise in blood pressure which returned to pre-infusion levels within 15 minutes after the infusion. No ECG changes were noted. Facial pallor was seen during all infusions, persisting longer with glypressin. Lysine vasopressin produced abdominal colic in six of eight patients, 750 lg glypressin in one of five patients and 2000 ,ug glypressin in four of eight patients.
Discussion
In patients bleeding from oesophageal varices, lysine vasopressin is used to reduce portal venous pressure in the hope that this will help stop bleeding. Tachyphylaxis and cardiotoxicity are well recognised problems associated with the use of lysine vasopressin and its ability to increase plasma plasminogen activator may constitute a further lesswell-recognised difficulty. Although lysine vasopressin did not produce frank fibrinolysis, as evidenced by a lack of increase in fibrin degradation products in the cirrhotic patients, the increased plasma plasminogen activator levels could lead to the lysis of fibrin deposited at the site of variceal bleeding. This might be of great importance in patients with more severe liver disease whose already raised plasma plasminogen activator levels are further increased. In contrast, GVP, in doses which will lower portal venous pressure (Vosmik et al., 1977) , did not increase the plasma levels of plasminogen activator. In addition, GVP has the advantages of a longer in vivo half-life and less cardiotoxicity than lysine vasopressin. Although the mode of action of GVP is uncertain, it probably acts as a depot from which lysine vasopressin is slowly released into the circulation. As GVP may have significant advantages over lysine vasopressin in the treatment of bleeding oesophageal varices, clinical trials would seem indicated to establish its therapeutic efficacy. 
